Emerging permanent filler technologies: focus on Aquamid

Yamauchi, Paul S.

doi:10.2147/ccid.s46650

Cited by 18 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PAAm is an uncharged, highly water-soluble and biocompatible polymer used in nanomedicine, 22,23 with stealth properties and also employed as permanent dermal filler (Aquamid®). 24 It thus fully meets the criteria for SC administration as recommended by Mrsny. 25 To demonstrate the proof of concept, we chose paclitaxel (Ptx), a representative hydrophobic irritant/vesicant anticancer drug widely used in the clinic.…”

Section: Introductionmentioning

confidence: 74%

A Polymer Prodrug Strategy to Switch from Intravenous to Subcutaneous Cancer Therapy for Irritant/Vesicant Drugs

Bordat

Boissenot

Ibrahim

et al. 2021

Preprint

View full text Add to dashboard Cite

Chemotherapy is almost exclusively administered via the intravenous (IV) route, which has serious limitations (e.g., patient discomfort, long hospital stays, need for trained staff, high cost, catheter failures, infections). Therefore, the development of effective and less costly chemotherapy that is more comfortable for the patient would revolutionize cancer therapy. While subcutaneous (SC) administration has the potential to meet these criteria, it is extremely restrictive as it cannot be applied to most anticancer drugs, such as irritant or vesicant ones, for local toxicity reasons. Herein, we report a facile, general and scalable approach for the SC administration of anticancer drugs through the design of well-defined hydrophilic polymer prodrugs. This was applied to the anticancer drug paclitaxel (Ptx) as a worst-case scenario due to its high hydrophobicity and vesicant properties (two factors promoting necrosis at the injection site), whereas polyacrylamide (PAAm) was chosen as a hydrophilic polymer for its biocompatibility and stealth properties. A small library of Ptx-based polymer prodrugs was designed by adjusting the nature of the linker (ester, diglycolate and carbonate), and then evaluated in terms of rheological/viscosity properties in aqueous solutions, drug release kinetics in PBS and in murine plasma, cytotoxicity on two different cancer cell lines, acute local and systemic toxicity, pharmacokinetics and biodistribution, and finally their anticancer efficacy. We demonstrated that Ptx-PAAm polymer prodrugs could be safely injected subcutaneously without inducing local toxicity while outperforming Taxol, the commercial formulation of Ptx, thus opening the door to the safe transposition from IV to SC chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 74%

A Polymer Prodrug Strategy to Switch from Intravenous to Subcutaneous Cancer Therapy for Irritant/Vesicant Drugs

Bordat

Boissenot

Ibrahim

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Products with a duration of more than 1 year are referred to as semipermanent products, and include calcium hydroxyapatite and poly-L-lactic acid fillers. Permanent fillers, such as silicone, PMMA, and polyacrylamide hydrogel (Aquamid ® ) have the longest activation time [6,7]. Importantly, the proper selection of soft-tissue fillers should be based on an understanding of their composition and properties [8].…”

Section: Discussionmentioning

confidence: 99%

The Characteristics and Safety of Previous Fillers in Secondary Rhinoplasty

Rho¹,

Yoon

Park

et al. 2018

Arch Aesthetic Plast Surg

View full text Add to dashboard Cite

Background Filler injection into the soft tissue of the nose is a useful technique for rhinoplasty. The individual characteristics of fillers determine which is best suited for a patient's specific circumstances. The objective of this study was to identify the characteristics of various fillers and to determine which fillers should be used for primary rhinoplasty in order to yield optimal long-term results. Methods Excluding patients treated with hyaluronic acid fillers, we reviewed 17 patients who underwent surgical rhinoplasty due to dissatisfaction with an injection using a different filler. After removing the previously injected filler, rhinoplasty was performed as part of the same procedure using a silicone or Surgiform ® prosthesis. Results Various previous fillers were used in the cohort. During the process of filler removal, skin perforation occurred in 2 cases and infection was observed in 1 case. In the other cases, rhinoplasty using a prosthesis was performed at the time of filler removal and no complications were observed. Conclusions We found that if surrounding tissue had been maintained stably, a simultaneous secondary operation using implants produced ideal results in most cases without any complications, despite the presence of residual remnant filler material.

show abstract

“… 22 Furthermore, even if serious AEs were not reported in that study, polyacrylamide can cause granuloma formation or delayed hypersensitivity reactions. 23 Hyaluronic acid (HA) gel, which has been proven to be effective and safe in various augmentation fields, is also reportedly effective as an injectable material for GPA. Kim et al .…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of newly developed cross-linked dextran gel injection for glans penis augmentation with a novel technique

Yang

Lee

et al. 2018

Asian J Androl

View full text Add to dashboard Cite

There is no safe and effective standard method for glans penis augmentation. Furthermore, there has been scant research on glans penis augmentation due to a poor understanding of glans anatomy, technical difficulty, and a lack of suitable substances for augmentation. Cross-linked dextran gel is a newly developed filler for soft-tissue augmentation. We evaluated the efficacy and safety of using a novel technique to inject cross-linked dextran gel for glans penis augmentation during a 24-week follow-up study. This prospective, single-arm, multicenter study enrolled twenty healthy adult men who underwent glans penis augmentation between June and August 2013. Cross-linked dextran gel was injected into the glans penis using a simple and easy technique. The sizes of the glans penis and individual satisfaction were assessed. Any adverse event was also reported. A total of 18 individuals were analyzed; two of them were lost to follow-up. The mean procedure time and injected volume were about 30 min and 6.6 ± 0.9 ml, respectively. The mean surface areas of the glans at baseline and 24 weeks were 20.0 ± 3.5 cm2 and 33.6 ± 5.4 cm2, respectively, representing a mean increase of 68.7% ± 14.0% (P < 0.001). Sixteen individuals (88.9%) were satisfied with the outcomes, and none were dissatisfied. There were no serious adverse events during the study. Cross-linked dextran gel injection for glans penis augmentation was easy and showed a significant augmentative effect on the glans penis, good durability, and was well tolerated without serious adverse events. Therefore, cross-linked dextran gel injection may be an effective, new technique for glans penis augmentation.

show abstract

Emerging permanent filler technologies: focus on Aquamid

Cited by 18 publications

References 19 publications

A Polymer Prodrug Strategy to Switch from Intravenous to Subcutaneous Cancer Therapy for Irritant/Vesicant Drugs

A Polymer Prodrug Strategy to Switch from Intravenous to Subcutaneous Cancer Therapy for Irritant/Vesicant Drugs

The Characteristics and Safety of Previous Fillers in Secondary Rhinoplasty

Efficacy and safety of newly developed cross-linked dextran gel injection for glans penis augmentation with a novel technique

Contact Info

Product

Resources

About